Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study

Autor: Shitara, Kohei *, Rha, Sun Young, Wyrwicz, Lucjan S, Oshima, Takashi, Karaseva, Nina, Osipov, Mikhail, Yasui, Hisateru, Yabusaki, Hiroshi, Afanasyev, Sergey, Park, Young-Kyu, Al-Batran, Salah-Eddin, Yoshikawa, Takaki, Yanez, Patricio, Di Bartolomeo, Maria, Lonardi, Sara, Tabernero, Josep, Van Cutsem, Eric, Janjigian, Yelena Y, Oh, Do-Youn, Xu, Jianming, Fang, Xiao, Shih, Chie-Schin, Bhagia, Pooja, Bang, Yung-Jue
Zdroj: In The Lancet Oncology February 2024 25(2):212-224
Databáze: ScienceDirect